ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.25 Billion JPY | -285.39% |
| 2022 | -1.88 Billion JPY | -196.86% |
| 2021 | 1.94 Billion JPY | -66.96% |
| 2020 | 5.88 Billion JPY | -35.55% |
| 2019 | 9.12 Billion JPY | 70.21% |
| 2018 | 5.36 Billion JPY | 172.49% |
| 2017 | -7.39 Billion JPY | 33.13% |
| 2016 | -11.06 Billion JPY | -4596.34% |
| 2015 | 246 Million JPY | 104.59% |
| 2014 | -5.35 Billion JPY | -97.57% |
| 2013 | -2.71 Billion JPY | -23.22% |
| 2012 | -2.2 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.75 Billion JPY | 48.17% |
| 2024 Q2 | -5.06 Billion JPY | -34.61% |
| 2023 Q2 | -7.12 Billion JPY | -57.09% |
| 2023 FY | -7.25 Billion JPY | -285.39% |
| 2023 Q4 | -7.25 Billion JPY | 1.31% |
| 2023 Q3 | -7.34 Billion JPY | -3.2% |
| 2023 Q1 | -4.53 Billion JPY | -140.86% |
| 2022 Q3 | -5.53 Billion JPY | -27.85% |
| 2022 Q4 | -1.88 Billion JPY | 65.98% |
| 2022 FY | -1.88 Billion JPY | -196.86% |
| 2022 Q1 | -4.44 Billion JPY | -328.77% |
| 2022 Q2 | -4.32 Billion JPY | 2.65% |
| 2021 FY | 1.94 Billion JPY | -66.96% |
| 2021 Q3 | -6.95 Billion JPY | -236.36% |
| 2021 Q1 | 5.45 Billion JPY | -7.26% |
| 2021 Q4 | 1.94 Billion JPY | 127.94% |
| 2021 Q2 | 5.09 Billion JPY | -6.51% |
| 2020 Q2 | 6.61 Billion JPY | -42.95% |
| 2020 FY | 5.88 Billion JPY | -35.55% |
| 2020 Q4 | 5.88 Billion JPY | -1.84% |
| 2020 Q1 | 11.6 Billion JPY | 27.13% |
| 2020 Q3 | 5.99 Billion JPY | -9.47% |
| 2019 Q2 | 12.6 Billion JPY | -7.67% |
| 2019 Q3 | 12.58 Billion JPY | -0.16% |
| 2019 FY | 9.12 Billion JPY | 70.21% |
| 2019 Q1 | 13.64 Billion JPY | 148.8% |
| 2019 Q4 | 9.12 Billion JPY | -27.48% |
| 2018 Q4 | 5.48 Billion JPY | -35.67% |
| 2018 Q2 | 7.39 Billion JPY | 98.23% |
| 2018 Q1 | 3.72 Billion JPY | 151.27% |
| 2018 FY | 5.36 Billion JPY | 172.49% |
| 2018 Q3 | 8.52 Billion JPY | 15.4% |
| 2017 Q1 | -9.65 Billion JPY | 12.68% |
| 2017 FY | -7.39 Billion JPY | 33.13% |
| 2017 Q4 | -7.27 Billion JPY | -3.09% |
| 2017 Q3 | -7.05 Billion JPY | 27.92% |
| 2017 Q2 | -9.78 Billion JPY | -1.31% |
| 2016 Q1 | -2.96 Billion JPY | -1306.5% |
| 2016 FY | -11.06 Billion JPY | -4596.34% |
| 2016 Q2 | -4.21 Billion JPY | -42.08% |
| 2016 Q4 | -11.06 Billion JPY | -15.74% |
| 2016 Q3 | -9.55 Billion JPY | -126.63% |
| 2015 Q2 | -1.93 Billion JPY | 51.69% |
| 2015 Q1 | -4.01 Billion JPY | 25.12% |
| 2015 Q4 | 246 Million JPY | 2.07% |
| 2015 Q3 | 241 Million JPY | 112.44% |
| 2015 FY | 246 Million JPY | 104.59% |
| 2014 Q4 | -5.35 Billion JPY | -49.29% |
| 2014 Q2 | -3.54 Billion JPY | -12.88% |
| 2014 Q1 | -3.13 Billion JPY | -15.63% |
| 2014 Q3 | -3.58 Billion JPY | -1.38% |
| 2014 FY | -5.35 Billion JPY | -97.57% |
| 2013 FY | -2.71 Billion JPY | -23.22% |
| 2013 Q1 | -2.32 Billion JPY | -5.68% |
| 2013 Q3 | -3.01 Billion JPY | -10.37% |
| 2013 Q4 | -2.71 Billion JPY | 9.96% |
| 2013 Q2 | -2.72 Billion JPY | -17.33% |
| 2012 Q4 | -2.2 Billion JPY | 48.1% |
| 2012 Q3 | -4.24 Billion JPY | 7.36% |
| 2012 Q2 | -4.57 Billion JPY | 0.0% |
| 2012 FY | -2.2 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 692.082% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.165% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 101.861% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 97.907% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | -103.501% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 82.795% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 88.202% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 92.594% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | -987.406% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 86.004% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 77.968% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 195.409% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 193.214% |
| Tsumura & Co. | 1.61 Billion JPY | 549.102% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 83.576% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 78.938% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 104.2% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 127.242% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 125.026% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 202.734% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 1130.256% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 221.045% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | -11.293% |
| MedRx Co., Ltd | -1.72 Billion JPY | -321.686% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 16.79% |
| Solasia Pharma K.K. | -668 Million JPY | -985.778% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | -393.087% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 112.832% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | -144.97% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 92.631% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 34.831% |